USP-NF Publishes Notice of Intent to Revise General Chapter <711> Dissolution
![Statistical Simulations for Enhanced Understanding of Analytical Performance - Live Webinar](files/eca/userImages/training.img/Z-ECA-Webinar-Statistical-Simulations.jpg)
Recommendation
Monday, 9 September 2024 14.00 - 16.00 h
In a USP–NF Compendial Notice published 29 October 2021, it was announced that the Dosage Forms Expert Committee intends to revise General Chapter <711> Dissolution. It is anticipated that the proposed revision will be published as an Interim Revision Announcement (IRA) in Pharmacopeial Forum 48(2) in March 2022, with the comment period ending on 31 May 2022. Thus, the revision may become official as early as on 01 September 2022.
"The purpose of this revision is to include an option for using a new USP Reference Standard, Dissolution Performance Verification Standard – Prednisone, to qualify the Dissolution Apparatus 1 (basket) and Dissolution Apparatus 2 (paddle), in addition to the existing USP Reference Standard Prednisone Tablets which is included in the current Chapter."
According to the Notice, the new reference standard will be more sensitive to operational and mechanical variables of instrument setup, less sensitive to media degassing, and more reproducible.
For further information, please see the Notice of Intent to Revise published on the USP-NF website.
Related GMP News
24.07.2024FDA Warning Letter to Chinese OTC Manufacturer for Lack of Analytical Test Data
10.07.2024Pharmeuropa: Two Revised Chapters on Dissolution Testing published for comments
03.07.2024FDA Warning Letter: GMP Requirements also apply to HPLC Analyses for Internal Use
12.06.2024NMPA Announcement on Application of ICH Q2(R2) and Q14 Principles
22.05.2024Q&As from the Live Online Training "Introduction to the AQCG's new AIQSV Guide" - Part 1
22.05.2024FDA Warning Letter to Contract Testing Laboratory in Uruguay due to Data Integrity Violations